Physician profile
Claude A Harmon
NPI 1114982717
$599.07
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $56.97 · 2021: $147 · 2022: $158 · 2023: $50.32 · 2024: $55.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $106.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $97.30 | 2021-2024 | |
| Myovant Sciences INC. | $73.84 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.80 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $59.33 | 2019-2024 | Tagrisso |
| Novocure INC. | $52.70 | 2020-2022 | |
| Tactile Systems Technology INC | $47.86 | 2019-2023 | Entre Plus, Flexitouch Plus |
| Palette Life Sciences, INC. | $37.44 | 2022 | |
| Boston Scientific Corporation | $33.21 | 2021-2023 | Spaceoar Vue System - 10ml |
| Urogen Pharma, INC. | $26.20 | 2022 | |
| Genzyme Corporation | $24.42 | 2022 | |
| Dendreon Pharmaceuticals LLC | $24.22 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $18.19 | 2022 | |
| Janssen Biotech, INC. | $16.30 | 2021 | |
| Fortovia Therapeutics, INC. | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claude Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.